Search Results - rachel+perret

1 Results

Sort By:

CCNA1 TCRs

CCNA1 TCRs for AML and solid tumors High-affinity HLA-A2 restricted TCRs for the treatment of AML and several solid tumors. Cancer-testis antigen cyclin A1 (CCNA1) is an alternative A-type cyclin and is thought to promote cell proliferation (specifically at the G1/S transition) and survival, has been shown to be leukemogenic in mice....

Published: 5/15/2025 | Updated: 12/12/2023 | Inventor(s): Rachel Perret, Philip Greenberg

Keywords(s): Immuno Oncology

Category(s): Cell Therapy